eftilagimod alpha,pembrolizumab
immutep,merck
['tacti-002', 'lcsm,(-blcsm)', 'sclc', 'nsclc', 'eftilagimod']
tacti-002: a phase-2 study of pembro+ eftilagimod (a lag-3 inhibitor) for advanced nsclc w/ unselected pd-l1 (n=114) --&gt; orr 36.8% irecist orr 42.7% dcr 73.7% md dor nr ; md pfs 6.9 mo. 28.1% orr in pd-l1 neg tumor #asco22 #lcsm 
Assistant Prof | Thoracic Oncology & Phase-I  @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own